Key result
EP inducibility in nonischemic cardiomyopathy is linked to ~160% higher risk of arrhythmic events.
Why the study?
Inducibility of ventricular arrhythmias is widely used to select ICD candidates but is believed not to predict outcomes in nonischemic cardiomyopathy patients.
Cohort (n=204)
Blinded outcome assessment
Hazard Ratio: 2.6
Absolute Event Rate: 34.5% vs 12%
p-value: p=0.014
May aid arrhythmic risk stratification in nonischemic cardiomyopathy; hypothesis-generating and should not yet change practice.
OBJECTIVES: We evaluated whether electrophysiologic (EP) inducibility predicts the subsequent occurrence of spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) in the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial. BACKGROUND: Inducibility of ventricular arrhythmias has been widely used as a risk marker to select implantable cardioverter defibrillator (ICD) candidates, but is believed not to be predictive in nonischemic cardiomyopathy patients. METHODS: In DEFINITE, patients randomized to the ICD arm, but not the conventional arm, underwent noninvasive EP testing via the ICD shortly after ICD implantation using up to three extrastimuli at three cycle lengths plus burst pacing. Inducibility was defined as monomorphic or polymorphic VT or VF lasting 15 seconds. Patients were followed for a median of 29 +/- 14 months (interquartile range = 2-41). An independent committee, blinded to inducibility status, characterized the rhythm triggering ICD shocks. RESULTS: Inducibility, found in 29 of 204 patients (VT in 13, VF in 16), was associated with diabetes (41.4% vs 20.6%, P = 0.014) and a slightly higher ejection fraction (23.2 +/- 5.9 vs 20.5 +/- 5.7, P = 0.021). In follow-up, 34.5% of the inducible group (10 of 29) experienced ICD therapy for VT or VF or arrhythmic death versus 12.0% (21 of 175) noninducible patients (hazard ratio = 2.60, P = 0.014). CONCLUSIONS: In DEFINITE patients, inducibility of either VT or VF was associated with an increased likelihood of subsequent ICD therapy for VT or VF, and should be one factor considered in risk stratifying nonischemic cardiomyopathy patients.
No takes yet. Share an insight, caveat, or question.
Daubert et al. (2009) conducted a cohort in Nonischemic cardiomyopathy (n=204). Electrophysiologic (EP) inducibility vs. Noninducible was evaluated on ICD therapy for VT or VF or arrhythmic death (HR 2.60, p=0.014). EP inducibility of VT or VF in nonischemic cardiomyopathy patients predicted subsequent ICD therapy or arrhythmic death compared to noninducible patients (34.5% vs 12.0%; HR 2.60, P=0.014).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: